The results of phase I clinical trial of the Araclon Biotech Alzheimer's vaccine support its continuation

by Grifols

This phase I blinded study did not evaluate the efficacy of the treatment. However, ABvac40 produced an immune response in more than 87% of patients who received the product during the trial.

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

El Plan Integral de eliminación de Hepa...

by Hospital Universitario Virgen de la Macarena

​Esta estrategia ha proporcionado facilidades de derivación desde a...

Photos Stream